Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen
β2-glycoprotein I (β2-GPI) is a major antigen for antiphospholipid antibodies (Abs, aPL) present in patients with antiphospholipid syndrome (APS). We recently reported (J. Lipid Res., 42: 697, 2001; J. Lipid Res., 43: 1486, 2002) that β2-GPI specifically binds to Cu2+-oxidized LDL (oxLDL) and that t...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2003-04-01
|
Series: | Journal of Lipid Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0022227520311615 |
id |
doaj-0164a5f6c85e4caebf18c4d8e4410e83 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kazuko Kobayashi Makoto Kishi Tatsuya Atsumi Maria L. Bertolaccini Hirofumi Makino Nobuo Sakairi Itaru Yamamoto Tatsuji Yasuda Munther A. Khamashta Graham R.V. Hughes Takao Koike Dennis R. Voelker Eiji Matsuura |
spellingShingle |
Kazuko Kobayashi Makoto Kishi Tatsuya Atsumi Maria L. Bertolaccini Hirofumi Makino Nobuo Sakairi Itaru Yamamoto Tatsuji Yasuda Munther A. Khamashta Graham R.V. Hughes Takao Koike Dennis R. Voelker Eiji Matsuura Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen Journal of Lipid Research antiphospholipid syndrome arterial thrombosis autoantibody |
author_facet |
Kazuko Kobayashi Makoto Kishi Tatsuya Atsumi Maria L. Bertolaccini Hirofumi Makino Nobuo Sakairi Itaru Yamamoto Tatsuji Yasuda Munther A. Khamashta Graham R.V. Hughes Takao Koike Dennis R. Voelker Eiji Matsuura |
author_sort |
Kazuko Kobayashi |
title |
Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen |
title_short |
Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen |
title_full |
Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen |
title_fullStr |
Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen |
title_full_unstemmed |
Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen |
title_sort |
circulating oxidized ldl forms complexes with β2-glycoprotein i: implication as an atherogenic autoantigen |
publisher |
Elsevier |
series |
Journal of Lipid Research |
issn |
0022-2275 |
publishDate |
2003-04-01 |
description |
β2-glycoprotein I (β2-GPI) is a major antigen for antiphospholipid antibodies (Abs, aPL) present in patients with antiphospholipid syndrome (APS). We recently reported (J. Lipid Res., 42: 697, 2001; J. Lipid Res., 43: 1486, 2002) that β2-GPI specifically binds to Cu2+-oxidized LDL (oxLDL) and that the β2-GPI ligands are ω-carboxylated 7-ketocholesteryl esters. In the present study, we demonstrate that oxLDL forms stable and nondissociable complexes with β2-GPI in serum, and that high serum levels of the complexes are associated with arterial thrombosis in APS. A conjugated ketone function at the 7-position of cholesterol as well as the ω-carboxyl function of the β2-GPI ligands was necessary for β2-GPI binding. The ligand-mediated noncovalent interaction of β2-GPI and oxLDL undergoes a temperature- and time-dependent conversion to much more stable but readily dissociable complexes in vitro at neutral pH. In contrast, stable and nondissociable β2-GPI-oxLDL complexes were frequently detected in sera from patients with APS and/or systemic lupus erythematodes. Both the presence of β2-GPI-oxLDL complexes and IgG Abs recognizing these complexes were strongly associated with arterial thrombosis. Further, these same Abs correlated with IgG immune complexes containing β2-GPI or LDL.Thus, the β2-GPI-oxLDL complexes acting as an autoantigen are closely associated with autoimmune-mediated atherogenesis. |
topic |
antiphospholipid syndrome arterial thrombosis autoantibody |
url |
http://www.sciencedirect.com/science/article/pii/S0022227520311615 |
work_keys_str_mv |
AT kazukokobayashi circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen AT makotokishi circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen AT tatsuyaatsumi circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen AT marialbertolaccini circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen AT hirofumimakino circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen AT nobuosakairi circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen AT itaruyamamoto circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen AT tatsujiyasuda circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen AT muntherakhamashta circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen AT grahamrvhughes circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen AT takaokoike circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen AT dennisrvoelker circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen AT eijimatsuura circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen |
_version_ |
1721506977291436032 |
spelling |
doaj-0164a5f6c85e4caebf18c4d8e4410e832021-04-27T04:39:07ZengElsevierJournal of Lipid Research0022-22752003-04-01444716726Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigenKazuko Kobayashi0Makoto Kishi1Tatsuya Atsumi2Maria L. Bertolaccini3Hirofumi Makino4Nobuo Sakairi5Itaru Yamamoto6Tatsuji Yasuda7Munther A. Khamashta8Graham R.V. Hughes9Takao Koike10Dennis R. Voelker11Eiji Matsuura12Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206β2-glycoprotein I (β2-GPI) is a major antigen for antiphospholipid antibodies (Abs, aPL) present in patients with antiphospholipid syndrome (APS). We recently reported (J. Lipid Res., 42: 697, 2001; J. Lipid Res., 43: 1486, 2002) that β2-GPI specifically binds to Cu2+-oxidized LDL (oxLDL) and that the β2-GPI ligands are ω-carboxylated 7-ketocholesteryl esters. In the present study, we demonstrate that oxLDL forms stable and nondissociable complexes with β2-GPI in serum, and that high serum levels of the complexes are associated with arterial thrombosis in APS. A conjugated ketone function at the 7-position of cholesterol as well as the ω-carboxyl function of the β2-GPI ligands was necessary for β2-GPI binding. The ligand-mediated noncovalent interaction of β2-GPI and oxLDL undergoes a temperature- and time-dependent conversion to much more stable but readily dissociable complexes in vitro at neutral pH. In contrast, stable and nondissociable β2-GPI-oxLDL complexes were frequently detected in sera from patients with APS and/or systemic lupus erythematodes. Both the presence of β2-GPI-oxLDL complexes and IgG Abs recognizing these complexes were strongly associated with arterial thrombosis. Further, these same Abs correlated with IgG immune complexes containing β2-GPI or LDL.Thus, the β2-GPI-oxLDL complexes acting as an autoantigen are closely associated with autoimmune-mediated atherogenesis.http://www.sciencedirect.com/science/article/pii/S0022227520311615antiphospholipid syndromearterial thrombosisautoantibody |